Cargando…

Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma

PURPOSE: In this study, we aimed to develop a novel liver function and inflammatory markers-based nomogram to predict recurrence-free survival (RFS) for AFP-negative (<20 ng/mL) HCC patients after curative resection. PATIENTS AND METHODS: A total of 166 pathologically confirmed AFP-negative HCC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Shuqi, Yu, Xi, Shan, Yuying, Fan, Rui, Wu, Shengdong, Lu, Caide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594894/
https://www.ncbi.nlm.nih.gov/pubmed/34805014
http://dx.doi.org/10.2147/JHC.S339707
_version_ 1784600080187129856
author Mao, Shuqi
Yu, Xi
Shan, Yuying
Fan, Rui
Wu, Shengdong
Lu, Caide
author_facet Mao, Shuqi
Yu, Xi
Shan, Yuying
Fan, Rui
Wu, Shengdong
Lu, Caide
author_sort Mao, Shuqi
collection PubMed
description PURPOSE: In this study, we aimed to develop a novel liver function and inflammatory markers-based nomogram to predict recurrence-free survival (RFS) for AFP-negative (<20 ng/mL) HCC patients after curative resection. PATIENTS AND METHODS: A total of 166 pathologically confirmed AFP-negative HCC patients were included at the Ningbo Medical Center Lihuili Hospital. A LASSO regression analysis was used for data dimensionality reduction and element selection. Univariate and multivariate Cox regression analyses were performed to identify the independent risk factors relevant to RFS. Finally, clinical nomogram prediction model for RFS of HCC was established. Nomogram performance was assessed via internal validation and calibration curve statistics. Receiver operating characteristic (ROC) and decision curve analysis (DCA) curve were used to validate the performance and clinical utility of the nomogram. RESULTS: Multivariate Cox regression analysis indicated that ALBI grade (hazard ratio, [HR] = 2.624, 95% confidence interval [CI]: 1.391–4.949, P = 0.003), INR (HR = 2.605, 95% CI: 1.061–6.396, P = 0.037), MLR (HR = 1.769, 95% CI: 1.073–2.915, P = 0.025) and MVI (HR = 4.726, 95% CI: 2.365–9.444, P < 0.001) were independent prognostic factors of RFS. Nomogram with independent factors was established and achieved a better concordance index of 0.753 (95% CI: 0.672–0.834) for predicting RFS. The ROC found that the area under curve (AUC) was consistent with the C-index and the sensitivity was 85.4%. The risk score calculated by nomogram could divide AFP-negative HCC patients into high-, moderate- and low-risk groups (P < 0.05). DCA analysis revealed that the nomogram could augment net benefits and exhibited a wider range of threshold probabilities by the risk stratification than the AJCC T and BCLC stage in the prediction of AFP-negative HCC recurrence. CONCLUSION: The ALBI grade- and MLR-based nomogram prognostic model for RFS showed high predictive accuracy in AFP-negative HCC patients after surgical resection.
format Online
Article
Text
id pubmed-8594894
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85948942021-11-18 Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma Mao, Shuqi Yu, Xi Shan, Yuying Fan, Rui Wu, Shengdong Lu, Caide J Hepatocell Carcinoma Original Research PURPOSE: In this study, we aimed to develop a novel liver function and inflammatory markers-based nomogram to predict recurrence-free survival (RFS) for AFP-negative (<20 ng/mL) HCC patients after curative resection. PATIENTS AND METHODS: A total of 166 pathologically confirmed AFP-negative HCC patients were included at the Ningbo Medical Center Lihuili Hospital. A LASSO regression analysis was used for data dimensionality reduction and element selection. Univariate and multivariate Cox regression analyses were performed to identify the independent risk factors relevant to RFS. Finally, clinical nomogram prediction model for RFS of HCC was established. Nomogram performance was assessed via internal validation and calibration curve statistics. Receiver operating characteristic (ROC) and decision curve analysis (DCA) curve were used to validate the performance and clinical utility of the nomogram. RESULTS: Multivariate Cox regression analysis indicated that ALBI grade (hazard ratio, [HR] = 2.624, 95% confidence interval [CI]: 1.391–4.949, P = 0.003), INR (HR = 2.605, 95% CI: 1.061–6.396, P = 0.037), MLR (HR = 1.769, 95% CI: 1.073–2.915, P = 0.025) and MVI (HR = 4.726, 95% CI: 2.365–9.444, P < 0.001) were independent prognostic factors of RFS. Nomogram with independent factors was established and achieved a better concordance index of 0.753 (95% CI: 0.672–0.834) for predicting RFS. The ROC found that the area under curve (AUC) was consistent with the C-index and the sensitivity was 85.4%. The risk score calculated by nomogram could divide AFP-negative HCC patients into high-, moderate- and low-risk groups (P < 0.05). DCA analysis revealed that the nomogram could augment net benefits and exhibited a wider range of threshold probabilities by the risk stratification than the AJCC T and BCLC stage in the prediction of AFP-negative HCC recurrence. CONCLUSION: The ALBI grade- and MLR-based nomogram prognostic model for RFS showed high predictive accuracy in AFP-negative HCC patients after surgical resection. Dove 2021-11-12 /pmc/articles/PMC8594894/ /pubmed/34805014 http://dx.doi.org/10.2147/JHC.S339707 Text en © 2021 Mao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mao, Shuqi
Yu, Xi
Shan, Yuying
Fan, Rui
Wu, Shengdong
Lu, Caide
Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
title Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
title_full Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
title_fullStr Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
title_full_unstemmed Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
title_short Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma
title_sort albumin-bilirubin (albi) and monocyte to lymphocyte ratio (mlr)-based nomogram model to predict tumor recurrence of afp-negative hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594894/
https://www.ncbi.nlm.nih.gov/pubmed/34805014
http://dx.doi.org/10.2147/JHC.S339707
work_keys_str_mv AT maoshuqi albuminbilirubinalbiandmonocytetolymphocyteratiomlrbasednomogrammodeltopredicttumorrecurrenceofafpnegativehepatocellularcarcinoma
AT yuxi albuminbilirubinalbiandmonocytetolymphocyteratiomlrbasednomogrammodeltopredicttumorrecurrenceofafpnegativehepatocellularcarcinoma
AT shanyuying albuminbilirubinalbiandmonocytetolymphocyteratiomlrbasednomogrammodeltopredicttumorrecurrenceofafpnegativehepatocellularcarcinoma
AT fanrui albuminbilirubinalbiandmonocytetolymphocyteratiomlrbasednomogrammodeltopredicttumorrecurrenceofafpnegativehepatocellularcarcinoma
AT wushengdong albuminbilirubinalbiandmonocytetolymphocyteratiomlrbasednomogrammodeltopredicttumorrecurrenceofafpnegativehepatocellularcarcinoma
AT lucaide albuminbilirubinalbiandmonocytetolymphocyteratiomlrbasednomogrammodeltopredicttumorrecurrenceofafpnegativehepatocellularcarcinoma